Cell Therapy
for All.
At TreeFrog, we are driven to make transformative regenerative medicine a reality, enabling the treatment of millions suffering around the world.
At TreeFrog, we are driven to make transformative regenerative medicine a reality, enabling the treatment of millions suffering around the world.
The next frontier
Every day, millions of people live with diseases that cannot be cured by today’s medicines. The promise of regenerative medicine is simple but profound: to help the body heal by restoring the cells lost to disease.
The potential is huge, particularly for diseases of major organs such as the central nervous system, heart, liver and pancreas.
9 million
Today, more than 9 million people live with Type 1 Diabetes,
10 million
over 10 million with Parkinson’s disease,
thousands
and thousands are on waiting lists for liver transplants.
No cure exists for any of these diseases. But hope does. Advances in regenerative medicine offer the possibility of moving beyond symptom management toward meaningful recovery, bringing a brighter future to patients and families, and changing their lives forever.
At TreeFrog, we see a future where these life-changing therapies are accessible to every patient who could benefit from them.
Our vision is to be the trusted engine for regenerative medicine — advancing restorative medicines through world class technology and deep therapeutic partnerships.
We have developed the only 3D biomimetic platform designed to overcome the challenges of regenerative medicine.
To achieve our purpose of bringing these transformative therapies to patients, we bring the best science, technology, people and partnerships together.
The GMPc platform solving the manufacturing bottleneck of cell therapy at scale.
Dive into the platform →A pipeline of owned and partnered assets in Parkinson’s Disease and Liver.
Explore the pipeline →The C-Stem™ platform, in-licensed or co-developed — choose your route to clinical scale.
Partner with us →A talented ecosystem of the best executives from biophysics, biology, engineering and industry.
Meet the team →Regenerative cell therapies have the potential to cure chronic and degenerative diseases. Yet today, most remain at early clinical development stages due to scalability limitations.
Manufacturing is complex and costly, production volumes are too low, and scaling compromises quality and consistency.
Breakthrough science
that cannot reach millions.